Stock listing

LSE:0LIF Ultragenyx Pharmaceutical Inc. Share Price

UK listing (LSE) of Ultragenyx Pharmaceutical Inc. · home listing NASDAQ:RARE

Follow Ultragenyx Pharmaceutical Inc. into a list and get an email when it puts out news.

Share price · LSE:0LIF

$16.77 USD +1.09 (+7.0%)

Close on Oct 27, 2026

Day range
$15.87 – $16.95 USDOct 27, 2026
Volume
5,542 sharesOct 27, 2026
Ultragenyx Pharmaceutical Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RARE · Home$16.78 USD-0.42 (-2.4%)2,801,874$17.26$17.63$16.71$17.20Close on Oct 29, 2026
LSE:0LIF$16.77 USD+1.09 (+7.0%)5,542$16.00$16.95$15.87$15.68Close on Oct 27, 2026
Frankfurt:UP0€14.24 EUR+0.34 (+2.4%)—€14.24€14.24€14.24€13.90Close on Oct 27, 2026
Ticker
LSE:0LIF
Asset type
Stock
Exchange
LSE
Currency
USD

What changed lately

Calls

Upcoming

  • Ultragenyx Pharmaceutical (NASDAQ:RARE) Q3 2026 Earnings Call

    Tue, Nov 03, 2026 · 5:00 PM ET

    Register

Replays

  • Ultragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 5:00 PM ET

    Watch Transcript

  • Ultragenyx Pharmaceutical (NASDAQ:RARE) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 5:00 PM ET

    Watch Transcript

  • Ultragenyx Pharmaceutical (NASDAQ:RARE) Q4 2025 Earnings Call

    Thu, Feb 12, 2026 · 5:00 PM ET

    Watch Transcript

Latest news

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

Oct 27, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Oct 14, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Oct 7, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Oct 2, 2026

Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A

Sep 18, 2026

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Sep 17, 2026

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Sep 2, 2026

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

Sep 1, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Aug 20, 2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 4, 2026

All Ultragenyx Pharmaceutical Inc. news

Decks

Ultragenyx Pharmaceutical Inc. on 6ix

News releases
37 in the last 12 months · 220 in all · newest Oct 27, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Aug 4, 2026
Decks
9 decks · latest Apr 30, 2026

Where Ultragenyx Pharmaceutical Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RARE · Home listingNASDAQUnited StatesUSD
LSE:0LIF · This pageLSEUnited KingdomUSD
gettex:UP0gettexGermanyEUR
BMV:RAREBMVMexicoMXN
LS Exchange:A1XCY0LS ExchangeGermanyEUR
Lang & Schwarz:A1XCY0Lang & SchwarzGermanyEUR
B3:R2AR34B3BrazilBRL
BIVA:RAREBIVAMexicoMXN
Frankfurt:UP0FrankfurtGermanyEUR
Tradegate:UP0TradegateGermanyEUR
BOATS:RAREBOATSUnited StatesUSD
BX Swiss:UP0BX SwissSwitzerlandCHF
Dusseldorf:UP0DusseldorfGermanyEUR
Hamburg:UP0HamburgGermanyEUR
Stuttgart:UP0StuttgartGermanyEUR
Hanover:UP0HanoverGermanyEUR
Xetra:UP0XetraGermanyEUR

Log in to ask 6ix AI your own questions about Ultragenyx Pharmaceutical Inc.